News: Brokerage

Marcus & Millichap arranges $4.2 million sale of medical office property

Bronx, NY Marcus & Millichap (NYSE: MMI), a leading commercial real estate brokerage firm specializing in investment sales, financing, research and advisory services, have completed the sale of a net-leased DaVita Dialysis property situated in the New York MSA for $4.2 million. 

“This property has been in the seller’s family since the 1950s, making it a particularly meaningful transaction,” said Daniel Chumbley. “After being home to their family business for decades, the site was redeveloped for DaVita Dialysis in 1995 and has served the community’s healthcare needs ever since. We received multiple offers above list price within just 10 days on the market, highlighting the strong demand for well-located healthcare assets.” 

Chumbley, Sean Sharko and Austin Weisenbeck, investment specialists in Marcus & Millichap’s Chicago Oak Brook office, had the exclusive listing to market the property on behalf of the seller, a multi-generational family corporation, and procured the buyer, a New York City-based group. John Horowitz is the firm’s broker of record in New York. 

“The buyer sees a clear opportunity to reposition the unused portion of the building, and we expect continued interest in similar properties as healthcare real estate remains a resilient and attractive investment, particularly in dense, supply-constrained markets like New York City,” added Chumbley. 

The 14,110 s/f property is located at 1615 Eastchester Road in the Bronx, in a busy medical corridor near five major hospitals. DaVita Dialysis has operated at the site since 1995 and runs a high-volume clinic six days a week. The lease is backed by a corporate guarantee and has more than four years remaining. It is near public transit, several universities and a large Amazon distribution center. 

READ ON THE GO
DIGITAL EDITIONS
Subscribe
Columns and Thought Leadership
Tri-state capital  migrates nationally amid  regulation pressure - by Reese Weaver

Tri-state capital migrates nationally amid regulation pressure - by Reese Weaver

New York tri-state multifamily investors are increasingly reallocating capital to less-regulated markets across the U.S. as rent control and legislative risk erode returns at home. With over 60% of New York City’s rental housing stock classified as rent-stabilized, the traditional value-add model — buying under-performing buildings,

The anticipated effect of Basel III and ISO 20022 implementation on commercial real estate - by Michael Zysman

The anticipated effect of Basel III and ISO 20022 implementation on commercial real estate - by Michael Zysman

July 1, 2025 is the deadline for US banks to begin to adopt Basel III banking standards and July 14, 2025 is the deadline for U.S. banks to adopt ISO 20022 messaging standards. Both will have a significant effect on the banking and commercial real estate (CRE) finance sectors.
The death of the generic offering memorandum: What buyers expect in 2025 - by Kimberly Zar Bloorian

The death of the generic offering memorandum: What buyers expect in 2025 - by Kimberly Zar Bloorian

There was a time when an offering memorandum (OM) was pretty bare bones, some photos, a few bullet points on income, and a rent roll thrown in at the back. That used to get the job done. Not anymore. In 2025, buyers are sharper, faster, and more selective. They’re looking
A fresh start - by Shallini Mehra and Amit Doshi

A fresh start - by Shallini Mehra and Amit Doshi

For the past several years, the New York City multifamily housing market has been defined by disruption. The combined impact of the HSTPA rent laws and a sharply higher interest rate environment has fundamentally reduced